


Bone Homeostasis and Pathology

Instructor: Roman Eliseev


Outline:

- Bone anatomy and composition
- Bone remodeling
- Factors regulating bone homeostasis
- Disorders of bone homeostasis:
 - Bone loss
 - Abnormal bone acquisition
- Methods and Mouse Models


Adult Skeleton



Adult Bone Architecture



Bone Histology




Bone Composition

Bone is a mineralized organic matrix composed of:

- Type I collagen and non-collagenous proteins (osteoid)
- Hydroxyapatite crystals ($\text{Ca}_5(\text{PO}_4)_3(\text{OH})$)


Osteoblasts



Bone-forming cells are osteoblasts (OB) that produce collagen I and deposit HA

Bone is Formed by Osteoblasts

OBs originate from Bone Marrow Stromal (a.k.a. Mesenchymal Stem) Cells (BMSC) and terminally differentiate into osteocytes (OT).



Bone is Resorbed by Osteoclasts






Image from SciencePhotoLibrary

Osteoclasts (OC) are bone resorbing multinucleated cells that originate from hematopoietic cells (monocyte/macrophage)




Homeostasis = equilibrium (Greek: ὁμοίως + στάσις)

Bone Formation vs Resorption = Dynamic Equilibrium (~10% of adult human skeleton is replaced annually)




Intact Bone

BMSC – bone marrow stromal
(a.k.a. mesenchymal stem) cell
OB – osteoblast
OT – osteocyte




Remodeling: Initial Phase




Remodeling: Resorption Pit


BMSC – bone marrow
stromal (a.k.a.
mesenchymal stem) cell
OB – osteoblast
OT – osteocyte
OC – osteoclast




Remodeling: Recruitment/Activation of BMSCs into Osteogenic Lineage



Remodeling: New Bone Formation




Histology of Bone Remodeling




TRAP Staining

Image – courtesy of Dr. J. Jonason

Phases of Remodeling




Factors Regulating Bone Homeostasis




Harada S and Rodan GA., (2003) *Nature* 423: 349-355.

Disorders of Bone Homeostasis



BONE LOSS



BONE GAIN

Disorders of Bone Homeostasis

- **Osteogenesis Imperfecta (*aka*, Brittle Bone Disease)**
 - Most commonly inherited bone disorder
 - Autosomal dominant mutations (over 800 identified) in the genes encoding the $\alpha 1$ and $\alpha 2$ chains of type I collagen
 - Clinical features include; skeletal fragility with increased fracture risk, blue sclera, hearing loss, dental imperfections, joint laxity
- **Osteopetrosis (*aka*, Marble Bone Disease)**
- **Osteoporosis**
- **Paget Disease**
- **Hyperparathyroidism**

Disorders of Bone Homeostasis

- **Osteogenesis Imperfecta (*aka*, Brittle Bone Disease)**
- **Osteopetrosis (*aka*, Marble Bone Disease)**
 - Rare genetic disease characterized by reduced bone resorption
 - Autosomal dominant or recessive mutations affecting osteoclast numbers or function
 - Clinical features include; frequent fractures, scoliosis, cranial nerve deficits, anemia
 - First genetic disease treated with a bone marrow transplant
- **Osteoporosis**
- **Paget Disease**
- **Hyperparathyroidism**

Disorders of Bone Homeostasis

- **Osteogenesis Imperfecta (*aka*, Brittle Bone Disease)**
- **Osteopetrosis (*aka*, Marble Bone Disease)**
- **Osteoporosis**
 - Common disease associated with decreased bone mass and increased fracture risk
 - Caused by both genetic and environmental factors
 - High societal burden with ~2 million fractures in the US annually due to osteoporosis, at a cost of around 22 billion dollars to treat
- **Paget Disease**
- **Hyperparathyroidism**


Disorders of Bone Homeostasis

- **Osteogenesis Imperfecta (*aka*, Brittle Bone Disease)**
- **Osteopetrosis (*aka*, Marble Bone Disease)**
- **Osteoporosis**
- **Paget's Disease**
 - Uncontrolled bone remodeling leading, ultimately, to areas of high bone mass that are architecturally unsound
 - Onset in late adulthood with causes unknown (likely to be a combination of genetic and environmental factors)
 - Most prominent clinical feature is bone pain, but can also lead to fracture, bone deformities, and nerve compression
- **Hyperparathyroidism**

Disorders of Bone Homeostasis

- **Osteogenesis Imperfecta (*aka*, Brittle Bone Disease)**
- **Osteopetrosis (*aka*, Marble Bone Disease)**
- **Osteoporosis**
- **Paget's Disease**
- **Hyperparathyroidism**
 - Excess parathyroid hormone (PTH) in the bloodstream due to over-activity of the parathyroid glands
 - Can be primary (due to hyperplasia or tumor of the glands) or secondary (due to hypocalcemia and compensatory increases in PTH secretion)
 - Results in increased bone resorption leading to increased fracture risk

Osteoporosis




Images from Bionews Texas


Epidemiology of Osteoporosis

- **Osteoporosis is found in 70% of the elderly population**
- **Post-menopausal women are most affected (25 million American women with Osteoporosis)**
- **1.9 million fractures annually due to low bone mass.**
- **1 of 3 women will develop a vertebral fracture by age 65, and 1 of 3 women will develop a hip fracture by age 85.**
- **\$22 billion dollars per year is spent on treating Osteoporosis.**

Epidemiology of Osteoporosis



C57Bl/6J mice:





Diagnosis of Osteoporosis



DEXA Dual Energy X-ray Absorptiometry

T-score = comparison to healthy young bone
Z-score = comparison to a reference group of the same age, race, and gender as the patient



Courtesy of Dr. J. Jonason

Treatment of Osteoporosis

Anti-resorptive drugs: Bisphosphonates

TABLE 3. FDA-approved indications for nitrogen-containing bisphosphonates

Drug	Postmenopausal osteoporosis		Glucocorticoid-induced osteoporosis		Men
	Prevention	Treatment	Prevention	Treatment	
Alendronate (Fosamax)	✓	✓		✓	✓
Risedronate (Actonel)	✓	✓	✓	✓	✓
Ibandronate (Boniva)	✓	✓			
Zoledronate (Reclast)	✓	✓	✓	✓	✓

Watts NB and Diab DL., (2010) Journal of Clinical Endocrinology and Metabolism. (95)4: 1555-1565.

Treatment of Osteoporosis

SERMS

SERMS: Selective Estrogen Receptor Modulators

Action: Drugs that act as estrogen agonists, activating the estrogen receptor in order to reduce osteoclast activity and bone resorption.

Drug: Raloxifene (Evista)

Dose: 60mg/day for many years

Notes: Not as effective as bisphosphonates. Only appears to protect spine and not hips from fracture.

Treatment of Osteoporosis

Bone anabolic agents


PTH: rPTH(1-34); Forteo. Under clinical investigation for the use in fracture non-union repair, treatment of osteoporosis.

BMPs: rBMP2 and rBMP7. Under clinical investigation and use for the repair of fracture non-union (InFuse). Recent complications in spinal fusion.

Neutralizing antibodies for Wnt inhibitors: anti-Dkk1 and anti-SOST. Under research and pre-clinical investigation for treatment of OA and fracture repair.




Lab Methods to Assess Bone Homeostasis

DEXA





Lab Methods to Assess Bone Homeostasis

micro-CT



Lab Methods to Assess Bone Homeostasis

Histology/Histomorphometry



Shum et al., PLoS One, 2016



Primary Measurements:

- Bone Area (B.Ar.) vs Total Area (T.Ar.)
- Surface, i.e. Bone Surface (BS)
- Cell Number per Surface/Area
 - =OB.N.
 - =OT.N.

**OsteoMeasure
or
Visiopharm**

Lab Methods to Assess Bone Homeostasis

Histology/Histomorphometry



Shum et al., PLoS One, 2016

Primary Measurements:

- Surface: Osteoclast Surface per Bone Surface (OC.S./BS)
- Cell Number: Osteoclast Number per Bone Surface (N.OC/BS)


Lab Methods to Assess Bone Homeostasis

Dynamic Bone Labeling (Bone Formation)

Mice are injected with Alizarin Red 10d before sacrifice & with Calcein 5d before sacrifice. Bone are frozen and sectioned. Labeled bone is visualized using fluorescence microscopy.

Derived Indices:

- Mineralizing Surface (MS/BS)
- Mineral Apposition Rate (MAR)
- Bone Formation Rate (BFR)



Shum et al., PLoS One, 2016

Lab Methods to Assess Bone Homeostasis

Bone Turnover Serum Markers

Formation:

P1NP

Resorption:

CTX

Per recommendation of the International Osteoporosis Foundation (IOF) and the International Federation for Clinical Chemistry (IFCC)

Useful Mouse Models

Osteolineage-specific Cre Models:

- BMSC: Prx1, Nestin, LepR, aSMA, Osx
- OB: Osx (early), Col1 3.2kb (early), Col1 2.3kb (late), OCN (late)
- OT: DMP1

Useful Mouse Models

Osteoclast-specific Cre Models:

- CD11b
- Lyzm
- Trap

Take-Home Message

Bone homeostasis is a dynamic equilibrium due to opposing actions and coupling of bone-forming OBs and bone-resorbing OCs.